We aimed to establish which low doses of IL@ would be safe and induce Treg cells in patients with type @ diabetes , considering that : ( @ ) type @ diabetes might be linked to alteration of the IL@/IL@R activation pathway ; ( @ ) activation of pathogenic Teff cells by IL@ could exacerbate disease ; and ( @ ) the safety of low-dose IL@ is not known in type @ diabetes .